Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: belimumab

Treating Lupus: Strategies, Treat to Target & Biologics

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—David A. Isenberg, MD, academic director of rheumatology, University College London, presented the ACR Systemic Lupus Erythematosus (SLE) State-of-the-Art Symposium at the 2018 ACR/ARHP Annual Meeting. Dr. Isenberg began by noting lupus is now widely covered in the news, but singer Selena Gomez has probably done the most to increase awareness of the disease; her…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingabataceptbelimumabTreat-to-Target

State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersPain SyndromesSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingFibromyalgiaOsteoporosisperioperative period

Diagnosing & Managing Pulmonary & Kidney Manifestations in Lupus

Thomas R. Collins  |  February 17, 2019

CHICAGO—In systemic lupus erythematosus (SLE), most types of severe pulmonary manifestations are relatively rare, but it’s crucial they be caught because of the potentially dire consequences, said Richard Silver, MD, professor in the Rheumatology Division at the Medical University of South Carolina, Charleston, at the 2018 ACR/ARHP Annual Meeting. Pulmonary Manifestations Parenchymal disease—seen in the…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual Meetingacute lupus pneumonitisbelimumabdiffuse alveolar hemorrhageparenchymal diseasepulmonary arterial hypertensionrituximab

The Non-Linear Path of Discovery, & Publicly Funded Research

Philip Seo, MD, MHS  |  November 19, 2018

Black powder was initially developed in 9th century China, by Taoists searching for the philosopher’s stone, which fans of Harry Potter will remember is the talisman that grants eternal life. The Chinese name for black powder literally translates as fire medicine. The chemical composition of black powder was first recorded in China during the 11th…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Research Funding

Ustekinumab May Be Effective for Lupus

Lara C. Pullen, PhD  |  November 12, 2018

New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupussystemic lupus erythematosus (SLE)ustekinumab

Coding Corner Question: Rheumatology Coding & Practice Quiz

From the College  |  October 18, 2018

1. A 45-year-old female patient with a diagnosis of primary osteoarthritis returns to the office for her second scheduled injection of sodium hyaluronate (Supartz). The nurse takes the patient’s vitals: weight is 185 lbs., height is 5’2”, and temperature is 98.2°F. The patient is prepped and given the injection. How should this encounter be coded?…

Filed under:Billing/CodingFrom the College Tagged with:Billing & Coding

The Case of a 13-Year-Old Girl with Life-Threatening Lupus Onset

Charles Radis, DO  |  October 18, 2018

I glanced up from Amanda Wolf’s chart as the emergency department nurse, followed by the lab technician (tech), followed by the electrocardiogram (ECG) tech flowed into cubicle No. 5. John Benner, MD, pulled up a chair to review the case with me at the nursing station. “Here’s what we’ve got. Thirteen-year-old girl with a one-week…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:cyclophosphamidekidney failurePericarditisSteroids

New Study Reveals Limitations in ANA Test Kits for Lupus

Kimberly Retzlaff  |  September 20, 2018

The variability in serological testing for antinuclear antibodies (ANA) is under investigation after unexpected findings were reported from clinical trials of new agents to treat systemic lupus erythematosus (SLE). In “Assay Variation in the Detection of Antinuclear Antibodies in the Sera of Patients with Established SLE,” David S. Pisetsky, MD, PhD, and his colleagues demonstrate…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:ANA testantinuclear antibody testassay

Promote Pregnancy Wellness: Data Can Help Guide Pregnancy Management in Lupus

Thomas R. Collins  |  September 10, 2018

AMSTERDAM—Clinicians who are counseling women with systemic lupus erythematosus (SLE) have the benefit of an array of new insights into factors linked with increased risk of pregnancy loss, how SLE therapies affect pregnancy and data on outcomes of children born to mothers with SLE, an expert said in a session at EULAR: the Annual European…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:HYDROXYCHLOROQUINELupus nephritispregnancypregnant womensystemic lupus erythematosus (SLE)

Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE

Lara C. Pullen, PhD  |  September 6, 2018

A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:baricitiniborgan damagerashsystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 15
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences